TIDMGSK

RNS Number : 6088N

GlaxoSmithKline PLC

21 January 2019

Issued: 21 January 2019, London UK - LSE Announcement

GSK announces succession plan to appoint new Chairman

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman and the Board has started the process to find a successor.

Sir Philip was appointed to the Board on 1(st) January 2015. He was appointed as Deputy Chairman from 1(st) April 2015 and as Chairman from 7(th) May 2015.

Sir Philip said: "It is a privilege to serve as Chairman of GSK. It is one of the UK's great companies and under Emma Walmsley's leadership, GSK has made very good progress with a new strategy and new approach to R&D. Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years and to lead the Board into this next phase for GSK."

Vindi Banga, GSK's Senior Independent Director, said: "The Group has a clear strategy, is delivering improved operating performance and has a clear pathway forward, this is a good time to start the process to find Philip's successor."

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

 
 GSK enquiries: 
 UK Media enquiries:   Simon Steel        +44 (0) 20 8047   (London) 
                                           5502 
                       Tim Foley          +44 (0) 20 8047   (London) 
                                           5502 
 Analyst/Investor      Sarah Elton-Farr   +44 (0) 208 047   (London) 
  enquiries:                               5194 
                       Danielle Smith     +44 (0) 20 8047   (London) 
                                           7562 
                       James Dodwell      +44 (0) 20 8047   (London) 
                                           2406 
                       Mel Foster-Hawes   +44 (0) 20 8047   (London) 
                                           0674 
                       Jeff McLaughlin    +1 215 751 7002   (Philadelphia) 
 
 
 Cautionary statements regarding forward-looking statements 
  GSK cautions investors that any forward-looking statements or 
  projections made by GSK, including those made in this announcement, 
  are subject to risks and uncertainties that may cause actual 
  results to differ materially from those projected. Such factors 
  include, but are not limited to, those described under Item 
  3.D Principal risks and uncertainties in the company's Annual 
  Report on Form 20-F for 2017. 
 
 
   Registered in England & Wales: 
   No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBBMFTMBATMRL

(END) Dow Jones Newswires

January 21, 2019 02:00 ET (07:00 GMT)

Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.